Umberto Vitolo
Umberto Vitolo is an expert in Hematology at Candiolo Cancer Institute (Italy). As of August 2026, ScienceLeadR ranks Umberto Vitolo in the top 1% of experts worldwide for Lymphoma and Lymphoproliferative Disorders. Umberto Vitolo has authored 542 publications, the most recent in 2026, and is an investigator in 37 clinical trials, 3 of them ongoing. SLR score: 2,200 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Immunology - Transplantation
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1989 - 2026
Number : 542
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma. PMID 42553584 — lymphoma, follicular, safety, lymphoma, rituximab, therapeutics, epcoritamab | Hemasphere | 2026 | 0 |
| Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma. PMID 42349017 — lymphoma, follicular, lymphoma, maintenance, aged, rituximab, lenalidomide, therapeutics | Blood Adv | 2026 | 0 |
| Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial. PMID 42285113 — cells, comorbidity, safety, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, neutropenia, multiple organ failure, drug-related side effects and adverse reactions, covid-19, pneumonia, lenalidomide, therapeutics, b-lymphocytes, infections, epcoritamab | Lancet Haematol | 2026 | 0 |
| Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial. PMID 42217458 — cells, prednisolone, safety, progression-free survival, prednisone, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, cyclophosphamide, doxorubicin, drug-related side effects and adverse reactions, rituximab, vincristine, lenalidomide, therapeutics, b-lymphocytes | Lancet | 2026 | 0 |
| Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network. PMID 42134356 — cells, microscopy, electron, scanning transmission, lymphoma, stem cells, maintenance, aged, drug-related side effects and adverse reactions, rituximab, lymphoma, mantle-cell, therapeutics, cell transplantation, stem cell transplantation, transplantation, infections | Lancet | 2026 | 0 |
Clinical Studies 37
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma NCT07256158 — radiotherapy, hodgkin disease, lymphoma, drug therapy, drug tapering, random allocation, chemotherapy | Phase 3 | Not yet recruiting | 2026 |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma NCT05409066 — injections, lymphoma, follicular, safety, hodgkin disease, lymphoma, neoplasms, drug-related side effects and adverse reactions, capsules, rituximab, lenalidomide, lymphoma, non-hodgkin, therapeutics, infusions, intravenous, injections, subcutaneous, epcoritamab | Phase 3 | Active not recruiting | 2022 |
| Tafasitamab Lenalidomide R CHOP Versus R CHOP in Newly Diagnosed High intermediate and High Risk DLBCL Patients NCT04824092 — cells, safety, saline solution, prednisone, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, cyclophosphamide, doxorubicin, solutions, rituximab, vincristine, antibodies, monoclonal, lenalidomide, b-lymphocytes | Phase 3 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map